Figure. Subset analysis: hazard ratio (95% confidence interval) for mortality with adjuvant radiation therapy (RT).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Mahmood U, Koshy M, Goloubeva O, Suntharalingam M. Adjuvant Radiation Therapy for High-Grade and/or Locally Advanced Major Salivary Gland Tumors. Arch Otolaryngol Head Neck Surg. 2011;137(10):1025–1030. doi:10.1001/archoto.2011.158
Author Affiliations: Departments of Radiation Oncology (Drs Mahmood, Koshy, and Suntharalingam) and Division of Biostatistics (Dr Goloubeva), Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore.
Objective To examine the effect of adjuvant radiation therapy (RT) on survival of high-grade and/or locally advanced malignant major salivary gland tumors (MMSGT).
Patients The study population comprised 2170 patients with high-grade (poorly differentiated or undifferentiated) and/or locally advanced MMSGT (T3/4 or N+).
Main Outcome Measures The Surveillance, Epidemiology, and End Results registry was used to obtained data for all patients 20 years or older who underwent surgery for high-grade and/or locally advanced nonmetastatic MMSGT between 1988 and 2005. Univariate and multivariable regression analyses were performed to identify factors associated with improved survival.
Results Seventy-two percent of patients received adjuvant RT, while 28% underwent surgery alone. Patients receiving adjuvant RT were younger and had higher T and N categories and grade. Multivariable analysis revealed significantly improved survival with adjuvant RT (HR for mortality, 0.76; 95% CI, 0.65-0.89; P < .001). Other factors associated with improved survival included younger age at diagnosis, less than radical surgery, certain histologic subtypes, lower grade, and lower T and N categories. Subset analyses found significantly improved survival with adjuvant RT among patients with both high-grade and locally advanced disease (P < .001), involvement of the parotid gland (P = .002), or squamous cell carcinoma (P = .004), with a survival benefit seen among patients with adenocarcinoma that did not reach significance (P = .06).
Conclusions Adjuvant RT is associated with improved survival for high-grade and/or locally advanced MMSGT based on analysis of this large, population-based database. Further prospective studies are warranted to examine the role of RT in the management of this disease.
Salivary gland tumors are rare entities that represent approximately 3% to 6% of head and neck neoplasms.1 Most are major salivary gland tumors that arise from the parotid, submandibular, or sublingual glands, while minor salivary gland tumors, arising from glands located throughout the submucosa of the upper aerodigestive tract, are even less common.2 Despite their rarity, salivary gland tumors display remarkable heterogeneity in terms of malignant potential and histologic differentiation. Histologic grading and classification is most commonly performed according to the recently revised World Health Organization classification scheme.3 Staging of major salivary gland tumors is also prognostic and is performed according to the American Joint Committee on Cancer (AJCC) TNM staging system.4
Primary treatment of nonmetastatic major salivary gland tumors typically involves surgical resection. Patients with benign/low-grade, completely resected tumors are generally treated with surgery alone, given their low recurrence rates and excellent prognosis. Retrospective data indicate a potential benefit for adjuvant radiation therapy (RT) in patients with malignant major salivary gland tumors (MMSGT) who have high-risk features (such as high grade, advanced stage, positive surgical margins, perineural/lymphovascular invasion, or recurrent tumors). While a number of retrospective studies suggest improved local control with adjuvant RT,5-16 few have identified a significant survival benefit.17-20 Given the variable inclusion criteria of these retrospective series, it has been difficult to make definitive therapeutic recommendations regarding adjuvant RT. Unfortunately, given the low incidence of MMSGT, randomized trials evaluating the effectiveness of adjuvant RT are unavailable.
The Surveillance, Epidemiology, and End Results (SEER) database is a cancer registry overseen by the National Cancer Institute (NCI) that is believed to be the authoritative source of population-based information regarding cancer incidence and survival in the United States.21 The SEER database is composed of 17 geographically distinct registries that house information from approximately 26% of the US population, although the data it stores are thought to be representative of the US population as a whole. It stores information on patient demographics, tumor characteristics, treatment course, and patient survival.
The purpose of this study was to examine the effect of adjuvant RT on overall survival of patients with high-grade and/or locally advanced MMSGT using this large, population-based database. We further hoped to elucidate which subgroups of patients benefit most from adjuvant RT.
The SEER database22 was queried using SEER*Stat software, version 6.5.1, to identify all adults (age ≥20 years) diagnosed between 1988 and 2005, who underwent surgical resection of high-grade (poorly differentiated or undifferentiated) and/or locally advanced (T3/4 or N+) MMGST. We purposefully excluded patients with low-grade and nonlocally advanced MMSGT because adjuvant RT is not typically recommended for such cases.
Data on survival, year of diagnosis, age at diagnosis, sex, tumor location, grade, histologic features, T and N categories, type of surgery, and administration of adjuvant RT were extracted for all patients. Survival was defined as time from date of diagnosis to date of death (in months). Tumor location and histologic subtype were analyzed according to the International Classification of Diseases for Oncology site and histology codes. Location was divided into the parotid gland (C07.9), the submandibular gland (C0.80), the sublingual gland (C08.1), and other (C0.88-0.89). Patients with minor salivary gland tumors were excluded. Grade was categorized as well differentiated, moderately differentiated, poorly differentiated, and undifferentiated/anaplastic. High grade included the latter 2 groupings. Histologic subtypes were categorized as adenocarcinoma (8140-7), adenoid cystic carcinoma (8200), mucoepidermoid carcinoma (8430), acinar cell carcinoma (8550-1), malignant mixed tumor/carcinoma in pleomorphic adenoma (8940-1), squamous cell carcinoma (8070-8), or other (all other codes). T and N categories were determined using extent of disease data available through the SEER Web site. The SEER database categorizes extent of surgical resection for salivary malignant neoplasms according to the following groupings: local tumor excision, less than total removal of the salivary gland, total removal of the salivary gland, or radical removal of the salivary gland. These designations are as defined by the performing surgeon. For the purposes of comparison, we divided surgery into less than radical resection vs radical resection.
Characteristics of patients receiving and not receiving adjuvant RT were compared using the unpaired t test for continuous variables and χ2 test for categorical variables. Univariate and multivariable Cox regression analyses were conducted to evaluate the effect of covariates on overall survival using year of diagnosis, age at diagnosis, sex, tumor location, grade, histologic subtype, T and N categories, type of surgery, and the presence or absence of adjuvant RT as plausible risk factors. Analysis was performed only on those patients with complete data available. Multivariable analyses were repeated on individual subgroups of patients (based on high-grade and/or locally advanced status, location, and histologic subtype) to assess plausible associations between adjuvant RT and survival within subsets.
Two-sided P values, hazard ratios (HRs) for death and the corresponding 95% CIs are reported herein. All statistical tests were done at the .05 level of significance. Data analyses were performed using SAS software (version 9.2; SAS Institute Inc, Cary, North Carolina).
A total of 2170 patients met the defined selection criteria: 51% of cases were high grade and 63% were locally advanced. In addition, 37% were both high grade and locally advanced. The median age for the study population was 68 years (range, 20-99 years). Sixty-eight percent of patients were male, while 32% were female. The majority of patients (84%) had involvement of the parotid gland, while submandibular gland and sublingual gland involvement were less common (15% and 1%, respectively). In terms of treatment, 77% had less than radical surgery, while 23% had radical surgery. Seventy-two percent of patients received adjuvant RT, while 28% underwent surgery alone. Patients receiving adjuvant RT were slightly younger and had higher T and N categories and grade. Moreover, the 2 groups were significantly different in terms of histologic subtypes (eg, patients with adenoid cystic were more likely to receive adjuvant RT). When analyzed by tumor location, the more aggressive histologic subtypes—adenocarcinoma, mucoepidermoid carcinoma, and squamous cell carcinoma—composed a larger proportion of cases in the sublingual (50%) and submandibular glands (45%) than in the parotid gland (36%). Patient characteristics are summarized in Table 1.
Univariate analysis revealed that younger age at diagnosis, female sex, less than radical surgery, lower grade, and lower T and N categories were significantly associated with improved survival. Also, there was significant variation in mortality based on histologic subtypes, with squamous cell carcinoma having the worst prognosis. Year of diagnosis, location, and adjuvant RT (P = .14) had no association with overall survival. The results of univariate analysis are summarized in Table 2.
Multivariable analysis revealed a significant association between improved survival and adjuvant RT (hazard ratio [HR] for mortality, 0.76; 95% confidence interval [CI], 0.65-0.89; P < .001). Moreover, significantly improved survival was associated with younger age at diagnosis, less than radical surgery, lower T and N categories, and lower grade. There were statistically significant differences in mortality noted among the various histologic subtypes. Year of diagnosis, sex, and location had no association with survival. The results of multivariable analysis are summarized in Table 3.
When analyzed by high-grade and ocally advanced status, multivariable analysis revealed significantly improved survival with the use of adjuvant RT among patients with both high-grade and locally advanced disease (P < .001), but not among patients with high-grade, nonlocally advanced disease (P = .28) or locally advanced, non–high-grade disease (P = .21).
When analyzed by location, multivariable analysis revealed significantly improved survival with the use of adjuvant RT among patients with tumors involving the parotid gland (P = .002) but not among patients with tumors involving the submandibular gland (P = .90). There were an insufficient number of analyzable patients with involvement of the sublingual gland to make definitive conclusions regarding a possible survival benefit with adjuvant RT in this subgroup.
When analyzed by histologic subtype, multivariable analysis revealed significantly improved survival with use of adjuvant RT among patients with squamous cell carcinoma (P = .004) and a survival benefit among patients with adenocarcinoma that did not reach significance (P = .06). The association between adjuvant RT and improved survival among patients with mucoepidermoid carcinoma failed to reach statistical significance (P = .22). Although there were trends toward improved survival with adjuvant RT among patients with adenoid cystic carcinoma, acinar cell carcinoma, and carcinoma ex pleomorphic adenoma and/or mixed malignant tumor, there were limited numbers of analyzable patients in these subgroups to make definitive conclusions regarding possible survival benefits with adjuvant RT.
The associations between adjuvant RT and mortality in the various subgroups of patients are summarized in the Figure.
Our analysis of the SEER database demonstrates an association between improved survival and use of adjuvant RT after surgical resection in patients with high-grade and/or locally advanced MMSGT. Given the higher T and N categories and grade seen among patients receiving RT, it is not surprising that this survival benefit was seen on multivariable rather than univariate analysis. The clearest survival benefits were seen among patients with both high-grade and locally advanced disease, involvement of the parotid gland, and squamous cell carcinoma or adenocarcinoma, although one must be cautious when interpreting the results of subset analysis because a number of subgroups had an inadequate number of analyzable patients to make definitive conclusions regarding the effect of adjuvant RT on survival in these subsets.
To our knowledge, our study represents the largest published data set examining the effect of adjuvant RT in patients with MMSGT. Bhattacharyya et al23 previously analyzed 903 patients extracted from the SEER database who were diagnosed between 1988 and 1998 and underwent surgery for parotid gland malignant tumors to identify determinants of survival. They found that adjuvant RT conferred survival benefit, which did not reach significance (P = .09). As opposed to our study, their subgroup analyses identified a significant survival benefit with adjuvant RT among patients with acinar cell carcinoma and a survival benefit among patients with squamous cell carcinoma that did not reach significance (P = .08). The discrepancies between their findings and ours are likely attributable to different patient inclusion criteria, with our study including patients with MMSGT involving the submandibular and sublingual glands but limited to patients with high-grade or locally advanced disease. Moreover, as our study spanned a longer period, it included a larger number of patients, yielding more statistical power to identify a survival benefit with adjuvant RT.
Only a few retrospective series have identified a significant survival benefit with adjuvant RT in patients with MMSGT.17-20 Armstrong et al17 performed a match-paired analysis of 46 patients with previously untreated MMSGT, who received surgery followed by adjuvant RT (compared with 46 patients treated with surgery only during an earlier era). They found a significant 5-year survival benefit with adjuvant RT among patients with stage III/IV disease (51.2% vs 9.5%), with a nonsignificant trend toward improved 5-year survival among patients with high-grade disease (57% vs 28%). In an analysis of 87 patients with MMSGT, North et al18 reported a significantly improved 5-year survival among patients receiving postoperative RT compared with those undergoing surgery alone (75% vs 59%). The majority of patients in this series had either locally advanced (51%) or high-grade disease (62%). Finally, the remaining 2 retrospective series identified survival benefits with adjuvant RT in specific subsets of patients with MMSGT (T4 adenoid cystic carcinomas19 and N0 ex pleomorphic adenomas20). Given the limited numbers of patients available in these retrospective series, however, they had insufficient statistical power to reliably and consistently identify precisely which subsets of patients experience survival benefits with adjuvant RT. Moreover, only 1 study identified a survival benefit with adjuvant RT on multivariable analysis, which controls for the simultaneous effects of multiple factors to assess the significance of each variable individually.18
Although we adjusted for all available patient and tumor characteristics in our analyses, our study was, nonetheless, limited by the information available in the SEER database. The SEER database is dependent on individual physician reporting for classification of patient, tumor, and treatment characteristics. In this way, it is representative of national patterns of cancer care; however, it is also subject to inconsistencies. For one, there is considerable variation in the histologic classification of MMSGT. As an example, the ability to differentiate the generally aggressive histologic features of mucoepidermoid carcinoma and squamous cell carcinoma becomes more difficult with increasing grade. Errors in reporting may, therefore, partly explain the survival benefit seen with RT in one histologic subtype vs the other. However, our study included a small proportion of patients with acinic cell or adenoid cystic carcinomas, histologic subtypes traditionally thought to be less aggressive although known to have occasional aggressive variants. Ultimately, we decided to simply include all patients in the SEER database diagnosed as having either high-grade and/or locally advanced MMSGT and thereafter perform exploratory subset analyses according to grade/locally advanced status, location, and histologic subtype because there is no way to correct for these limitations in the SEER database. Moreover, the SEER database is also dependent on physician reporting to provide certain details of patient treatment. For example, as extent of surgery is somewhat subjective and defined by the performing surgeon, this is a potential source of error in our study, the exact impact of which is unknown.
In addition, as with all SEER studies, we were unable to include certain pathologic information such as margin status, presence of perineural or lymphovascular invasion, or intraoperative tumor spillage. The lack of such information may explain why those who underwent less than radical surgery fared better than those who underwent radical surgery, since the latter are more likely to have these high-risk pathologic characteristics. Intuitively, these high-risk pathologic characteristics were likely more prevalent among patients receiving adjuvant RT because these patients had higher T and N categories and grade. Should this information have been available, perhaps the survival benefit seen with adjuvant RT would have been even more pronounced or significant among more patient subgroups. However, as with any nonrandomized study, there is the risk of a selection bias as physicians may be more likely to treat those who have better performance status and fewer comorbidities.
Similarly, local control and distant metastasis data were not available for analysis. As such, it should be pointed out that, although multivariable analysis did not confirm improved survival with adjuvant RT in certain subgroups, this does not exclude the possibility of a clinically important local control benefit with adjuvant RT in these subsets. Moreover, the lack of such data limits our ability to speculate as to the exact mechanism of improved outcomes with adjuvant RT (ie, whether from improved local control and/or decreased distant metastasis).
Finally, although there was no information available regarding the use of systemic therapy, given the poor responses seen with chemotherapy in this disease, it plays little role in the adjuvant setting.24 Therefore, inclusion of chemotherapy data would likely not alter our results significantly.
In conclusion, our analysis of the SEER database revealed a significant association between improved survival and use of adjuvant RT in the treatment of patients with high-grade and/or locally advanced MMSGT. Patients with the clearest benefit from adjuvant RT included those with both high-grade and locally advanced disease, involvement of the parotid gland, squamous cell carcinoma, or adenocarcinoma, although many of the other subsets likely had inadequate patient numbers. However, given the rarity of MMSGT, a randomized trial may be impractical; further prospective studies are warranted to examine the role of RT in the management of this disease.
Correspondence: Usama Mahmood, MD, Department of Radiation Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, 22 S Greene St, Baltimore, MD 21201 (firstname.lastname@example.org).
Submitted for Publication: February 22, 2011; final revision received July 13, 2011; accepted July 14, 2011.
Author Contributions: Dr Mahmood had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Mahmood and Suntharalingam. Acquisition of data: Mahmood. Analysis and interpretation of data: Mahmood, Koshy, and Goloubeva. Drafting of the manuscript: Mahmood, Koshy, and Goloubeva. Critical revision of the manuscript for important intellectual content: Mahmood and Suntharalingam. Statistical analysis: Mahmood, Koshy, and Goloubeva. Administrative, technical, and material support: Koshy. Study supervision: Mahmood and Suntharalingam.
Financial Disclosure: None reported.
Previous Presentation: This study was presented at the American Society of Therapeutic Radiation Oncology (ASTRO) 2009 Annual Meeting; November 1-5, 2009; Chicago, Illinois.
Additional Contributions: Sana Ahmedani, MBA, assisted with figure and table formatting.